Boardroom Alpha
10-K primary document
STIM · Annual Report (Form 10-K) · Filed March 17, 2026

Neuronetics Inc — 10-K exhibit

stim-20251231xex10d54.htm

Exhibit 10.44

​

THIRD AMENDMENT TO RESEARCH COLLABORATION AGREEMENT (“Amendment”)

​

This Amendment is dated 10 December 2025 (“Effective Date”)

Between:

(1)COMPASS PATHFINDER LIMITED, a company incorporated in England and Wales under company number 10229259, with its registered offices at 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, United Kingdom (“Compass”); and

​

(2)TMS NEUROHEALTH CENTERS, INC., a Delaware corporation with an address at 8401 Greensboro Drive, Suite 425, Tysons Corner, VA 22102 and its affiliated medical practices (together “GTMS”),

each a “Party” and together the “Parties”.

​

WHEREAS:

(A)The Parties entered into a Research Collaboration Agreement as of 15 December 2023 (“Agreement”) which included a Collaboration Plan (as defined in the Agreement).

​

(B)Thereafter, the Parties entered into a first amendment as of 08 August 2024 to modify the deliverables and research activities contained in the Collaboration Plan (the “First Amendment”);

​

(C)The Parties then entered into a second amendment, as of 14 February 2025, to further modify the deliverables and research activities contained in the Collaboration Plan (the “Second Amendment”);

​

(D)The Steering Committee (as defined in the Agreement) has since agreed to certain further amendments to the deliverables and research activities contained in the Collaboration Plan; and

​

(E)The Parties now wish to memorialize such amendments by updating the Collaboration Plan.

​

NOW, THEREFORE, in consideration of the foregoing and for valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Compass and GTMS, intending to be legally bound, agree as follows:

​


1.Definitions

Unless otherwise defined in this Amendment, all capitalized terms used in this Amendment shall have the meaning ascribed to them in the Agreement.

​

2.Collaboration Plan
2.1The fee schedule accompanying the Collaboration Plan at “Section E – Compensation” shall be updated as follows:

​

2.1.1Activity descriptions, deliverables, and associated payments for Milestones 5-8 shall be updated as reflected in Appendix A.

​

3.No Further Amendments

Except as expressly modified herein, there are no further amendments to the Agreement, which remains in full force and effect.

​

4.Counterparts; Electronic Execution

This Amendment may be executed in two (2) or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. Furthermore, the words “execution,” “signed,” “signature,” and words of similar import shall be deemed to include electronic or digital signatures, each of which shall be of the same effect, validity, and enforceability as manually executed signatures, as the case may be, to the extent and as provided for under applicable law.

​

[SIGNATURE PAGE FOLLOWS]

​

​


IN WITNESS THEREOF, the Parties hereto have executed this Amendment as of the Effective Date by proper persons thereunto duly authorized.

​

COMPASS PATHFINDER LIMITED

​

/s/ Kabir Nath

Name: Kabir Nath

Title: CEO

Date: 12/16/2025

​

GTMS

​

/s/ Cory Anderson

Name: Cory Anderson

Title: Chief Technology Officer

Date: 12/15/2025


Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer